Last reviewed · How we verify

Remifentanil + propofol

Nanfang Hospital, Southern Medical University · Phase 3 active Small molecule

Remifentanil is an opioid agonist that provides analgesia and sedation, while propofol is a GABAergic hypnotic agent that induces and maintains anesthesia.

Remifentanil is an opioid agonist that provides analgesia and sedation, while propofol is a GABAergic hypnotic agent that induces and maintains anesthesia. Used for Induction and maintenance of general anesthesia, Sedation and analgesia in mechanically ventilated patients.

At a glance

Generic nameRemifentanil + propofol
SponsorNanfang Hospital, Southern Medical University
Drug classOpioid agonist + GABA-A receptor positive allosteric modulator
TargetMu-opioid receptor (remifentanil); GABA-A receptor (propofol)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhasePhase 3

Mechanism of action

Remifentanil binds to mu-opioid receptors in the central nervous system to produce rapid-onset analgesia and sedation with ultra-short duration due to rapid ester metabolism. Propofol acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission to produce hypnosis and unconsciousness. Together, this combination provides balanced anesthesia with opioid analgesia and hypnotic sedation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results